POETYK PSO-LTE: Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (clinicaltrials.gov) - Sep 11, 2026 - P3 | N=1466 | Completed | Sponsor: Bristol-Myers Squibb | Active, not recruiting ➔ Completed
Trial completion • Dermatology • Immunology • Psoriasis
|